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Background: Despite controversy about the benefits of routine prostate specific antigen (PSA) testing, rates of
participation continue to rise. It is important to ensure that men are fully informed about the potential risks
associated with this test. Little is known about the processes of shared decision making for PSA testing in the
family practice setting. This study aimed to explore men’s experiences of PSA testing participation and risk
disclosure for PSA testing.
Methods: A cross-sectional survey of male family practice attendees aged 40 years or older, with no previous
history of prostate cancer, between June 2010 and November 2011. Questions related to whether participants had
undertaken PSA testing or discussed this with their doctor over the past 5 years, whether the patient or doctor had
initiated the discussion, reasons for undergoing testing, and whether their doctor had discussed particular risks
associated with PSA testing.
Results: Sixty-seven percent (215/320) of men recalled having a PSA test in the past five years. Of the respondents
who reported not having a test, 14% had discussed it with their doctor. The main reasons for having a PSA test
were doctor recommendation and wanting to keep up to date with health tests. Thirty-eight percent or fewer
respondents reported being advised of each potential risk.
Conclusions: Despite debate over the benefits of routine PSA testing, a high proportion of male family practice
attendees report undertaking this test. Risks associated with testing appear to be poorly disclosed by general
practitioners. These results suggest the need to improve the quality of informed consent for PSA testing in the
family practice setting.
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Prostate cancer is one of the most common cancers
among men world-wide [1]. Elevated levels of prostate
specific antigen (PSA) in the blood can indicate the pres-
ence of prostate cancer as well as a number of other be-
nign conditions. As such, there has been increased use
of PSA testing for the detection of prostate cancer in the* Correspondence: Mariko.Carey@newcastle.edu.au
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reproduction in any medium, provided the orpopulation. There is significant variation across countries
in rates of PSA testing to detect the disease in its early
stages [2]. An American population survey reported that
41% of men aged 50 or older reported having had a PSA
test within the past year [3]. Health service use data
indicates that approximately 21% of Australian men
underwent PSA testing in 2006 [2]; while only 6% of
men aged 45–89 in the family practice setting in the
United Kingdom undergo testing each year [4,5].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Despite the relatively high rates of PSA testing, routine
screening remains controversial [6]. The results of the
two largest clinical trials are conflicting about whether
routine screening results in decreased mortality [7,8]. A
recent meta-analysis concluded that current evidence
does not support the use of the PSA test for screening
[9]. One recent randomized controlled trial estimated
that 1068 men would need to be screened twice during a
nine year period to save one life, and 48 men would
need to be treated for prostate cancer to save one life
[10]. Currently the Urological Society of Australia and
New Zealand (USANZ) does not recommend routine
PSA testing [11]. However it does recommend PSA test-
ing, with digital rectal examination, be offered to men
aged 55–69 years after providing information about the
risks and benefits of such testing [11]. The US Prevent-
ive Services Task Force does not recommend PSA test-
ing for asymptomatic men regardless of age [12].
What risks should be disclosed to patients making a
decision about PSA testing?
There are a number of risk and benefits with undertak-
ing PSA testing. Potential risks of PSA testing include a
high false positive rate (up to 76%), an indicator for bi-
opsy which carries an associated risk of infection, bleed-
ing and pain [13]. Since most men with prostate cancer
will die from other causes before their cancer becomes
symptomatic, over-diagnosis and over-treatment are sig-
nificant concerns [6]. Rates of over-diagnosis have been
estimated to range from 23% to 42% of all prostate can-
cer detected through screening [6]. Up to 90% of men
with low PSA values receive early intervention [14,15].
Over-treatment for prostate cancer carries a significant
risk of adverse effects. Surgical treatment by radical pros-
tatectomy has not been found to reduce mortality com-
pared to no treatment, and is associated with high rates of
erectile dysfunction and urinary incontinence [16,17].
How well are risks disclosed in practice?
Prior research suggests that men’s knowledge of the ben-
efits and risks of PSA testing is poor [18,19]. The 2000
American National Health Interview Survey found that
33% of the 8087 participating men aged 40 or older
reported having received a PSA test [20]. However,
only 65% of those screened reported discussing the risk
and benefits of testing with their doctor. Similarly, an
Australian study indicated that only 62% of men screened
in the past 5 years recalled a discussion about the risks
and benefits of testing [21].
Given that the majority of research has been under-
taken in the US, it is unclear how generalizable these
findings may be to the experiences of men in family prac-
tice settings in other countries. The Australian health caresetting, for example, differs substantially to the US, with
access to general practitioners (GPs) available at little or
no cost to the patient. It is therefore useful to investigate
whether associations between high socioeconomic status
and increased screening rates identified in previous re-
search are applicable to the Australian setting [4,5,18]. All
Australians have access to Medicare, a government funded
universal health insurance program that reimburses pa-
tients for fees incurred for core clinical services [22]. The
vast majority of GP services are directly billed from the
provider to the Medicare (and hence delivered at no cost
to the patient). Private health insurance underwrites access
to both allied health professionals and to private hospital
inpatient care [22].
The current study was conducted as part of a large
cross sectional study exploring screening participation
for cancer and cardiovascular disease among Australian
family practice attendees [23]. A subsample of male
participants was asked to complete questions related to
PSA testing. We aimed to: 1) identify the proportion of
male family practice patients who report having a)
undergone a PSA test; or b) discussed PSA testing with
their doctor, in the last 5 years; 2) identify factors associ-
ated with having a test and perceived reasons for having
a test; and 3) explore how discussion of PSA testing was
initiated and the proportion of patients who were told
about risks associated with testing.
Methods
Study design and setting
A cross-sectional study, conducted with patients pre-
senting to 12 family practices in Australia between 16th
June 2010 and 18th November 2011.
Recruitment of family practices
Geographic areas within 20 kilometers from a University
Department of Family Practice were selected in Newcastle
and Sydney. A list of practices was generated using the
Medical Directory of Australia and the Yellow Pages tele-
phone directory. In Melbourne, a random list of practices
within a region of the city corresponding to the boundaries
of a Division of General Practice was generated from a
commercially available database, Australasian Medical Pub-
lishing Company (AMPCo) [24]. Practices were mailed an
invitation to participate in the study which was followed
up with one to three telephone calls and, if requested, in-
person visits, by a member of the research team. Practices
were approached until four in each region consented.
Family practices were eligible if a sufficient number of GPs
(equal to two, full time equivalent) agreed to take part.
Participants
Male patients aged 40 or older, without a history of
prostate cancer, who were presenting for family practice
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were able to provide informed consent were presented
with questions related to PSA testing.
Recruitment
Patients were approached by a research assistant while
waiting for their family practice appointment. Informed
consent to participate in a touchscreen computer survey
was obtained from all participants. Participants were
given a paper copy of the information sheet and also
presented with this information on the touchscreen
computer used to administer the survey. Prior to com-
mencing the survey, participants were asked to touch
“NEXT” onscreen to indicate that they consented to par-
ticipating in the study. Consenting patients completed a
brief survey prior to their consultation. Patients were
able to exit the survey if called into their appointment.
Measures
The questionnaire was administered using a DELL Lati-
tude XT2 laptop. Patients touched their selected re-
sponses using their finger or a stylus.
Demographic and medical characteristics
Self-report data were collected on age, gender, education,
possession of a Veteran’s Affairs Treatment Entitlement
Card or Health Care Card, and private health insurance.
Veteran’s Affairs Entitlement Cards entitle veterans, war
widows/widowers and dependents to free access to certain
health services, while Health Care Cards enable access to
subsidized prescription medicines and medical services
funded by the Australian Government. Participants were
asked whether they had ever been told by a doctor or
nurse that they had: high blood pressure, high cholesterol,
heart problems, diabetes, kidney disease, depression, can-
cer, stroke or chronic pain.
Discussion of PSA testing
Respondents were asked whether they had discussed
PSA testing with their doctor within the last 5 years, and
if so, who the discussion was initiated by.
Discussion of risk of PSA testing
The following introduction was provided: “An elevated
PSA reading may indicate both prostate cancer and
benign (non-cancerous) conditions. PSA levels alone do
not give enough information to diagnose prostate can-
cer. However, GPs will take the result of the PSA test
into account when deciding whether to check for further
signs of cancer. The following question asks you about
what your doctor told you the first time you discussed
PSA testing.” Respondents were then presented with a
series of statements and asked to indicate whether the
potential risk described had been discussed.PSA test history
Respondents were asked whether they had a PSA test
within the last 5 years.Reasons for undertaking PSA testing
Those who reported having had a PSA test were asked
to rank their top three reasons why, from: “My doctor
suggested it because of the symptoms I had”, “I was wor-
ried because prostate cancer runs in my family”, “I heard
about the test on TV, radio or newspaper”, “My partner/
family member suggested I get tested”, “I like to keep up
to date with all kinds of health tests”.Ethical approval
Human Research Ethics Committee approval was ob-
tained from the University of Newcastle, the University
of New South Wales and Monash University.Statistical analysis
Categorical measures were summarised using frequen-
cies and percentages. Continuous measures were sum-
marised using means and standard deviations. Simple
logistic regression was used to examine whether the fol-
lowing variables were associated with undergoing a PSA
test: age category (40–49, 50–59, 60–69, 70 plus), having
a health care card or Veteran’s Affairs card (yes/no),
education level (high school certificate or below, Tech-
nical and Further Education (TAFE) or diploma, univer-
sity or postgraduate), and number of chronic conditions.
Multiple logistic regression was used to examine these
relationships together.Results
Practice response rate
Forty-eight practices were invited to participate, with 12
(25%) agreeing. Participating practices had on average
6.8 family physicians per practice and 80% employed at
least one nurse. All were located in metropolitan areas.Patient response rate
Of the eligible patients approached, 1269 agreed to par-
ticipate giving a consent rate of 88%. A total of 371 pa-
tients were male and aged 40 and above. Of those, 320
(86.3%) completed the questions relevant to PSA testing,
51 patients were called to their GP prior to commen-
cing. There was no significant difference in the pro-
portion of consenters and non-consenters (χ2(1): 0.5211;
p-value: 0.470). Of the 320 participants completing the
prostate screening questions, most (72%) were aged be-
tween 40 and 70. Just over half (51%) had private health
insurance. Demographic characteristics of consenting
patients are shown in Table 1.








Primary school 4 (1.5%)
Some high school 25 (9.1%)
Year 10 37 (14%)
Completed high school certificate 34 (12%)
Technical and further education (TAFE) certificate or Diploma* 53 (19%)
University or other tertiary qualifications 84 (31%)
Postgraduate qualifications 25 (9.1%)
Other 12 (4.4%)
New patient
Veterans affairs card 22 (6.9%)
Health care card 82 (26%)
Private health insurance 162 (51%)
Number of chronic conditions 1.47(1.23)
*TAFE is attended as part of trade education for apprentices.
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testing within the past 5 years
Of the 320 respondents, the majority (n = 215, 67%) re-
ported having had a PSA test within the past 5 years. Of
the remaining 105, 15 (14%) had discussed PSA testing
with their doctor. Ten of these 15 participants reported
that they had initiated the discussion of PSA testing with
their doctor.Table 2 Factors associated with having undertaken a prostate
PSA Test in last 5
Variable No (n = 105) Yes (n
Age group 70+ 29 (32%) 63
40-49 39 (50%) 39
50-59 18 (24%) 57
60-69 19 (25%) 56
Health care/benefits card Yes 26 (32%) 56
No 79 (33%) 159
Education HSC or below 43 (38%) 69
TAFE / Diploma 16 (30%) 37
University / Post Grad 33 (30%) 76
Private health insurance Yes 50 (31%) 112
No 55 (35%) 103
Number of Chronic conditions Mean (Std) 1.21 (1.131) 1.60Factors associated with PSA testing
Logistic regression analyses explored whether there was
evidence for an association between socio-demographic or
medical history factors and having undergone a PSA test
within the last 5 years. Those who reported having a test
within the last 5 years were more likely to have a greater
number of chronic conditions than those who had not
(OR = 1.32, 95% CI 1.07 to 1.63, p = 0.0103) (see Table 2).
However, after including the other variables of interest in a
multiple logistic regression model neither the number of
chronic conditions nor any of the other variables were
significantly associated with PSA testing within the last
5 years.
Reasons for undergoing PSA testing
Of the 215 men who reported undergoing a test within
the past 5 years, 203 also indicated reasons for undertak-
ing testing. Missing data were due to respondents exiting
the survey to attend their GP appointment. The top
three reasons are reported in Figure 1.
Of the 230 participants who had discussed PSA testing
or undergone a test within the last 5 years, 228 indicated
how their first discussion of PSA testing with their doc-
tor was initiated. Just over half [n = 123, 54% (95% CI
46.4 to 60.5)] reported that this was doctor initiated, 74
[32%, (95% CI 26.3 to 38.6)] reported that they had initi-
ated the discussion, while 31 [14%, 95% CI 9.1 to 18.1)]
could not remember.
Disclosure of risks regarding PSA testing
Of the 230 respondents who reported having undergone
or discussed testing within the last 5 years, 188 answered
at least one question related to whether their doctor had
provided advice about possible risks. Participants could
skip these questions, resulting in some missing data asspecific antigen test in the last five years
years Simple regression Multiple regression
= 215) Odds ratio (95% CI) P-value Odds Ratio (95% CI) P-value
(68%) . .
(50%) 0.46 (0.25, 0.86) 0.0150 0.48 (0.22, 1.04) 0.0619
(76%) 1.46 (0.73, 2.9) 0.2839 1.28 (0.58, 2.81) 0.5410
(75%) 1.36 (0.69, 2.68) 0.3804 1.5 (0.7, 3.25) 0.2983
(68%) . .
(67%) 0.93 (0.55, 1.6) 0.8048 0.92 (0.51, 1.67) 0.7939
(62%) . .
(70%) 1.44 (0.72, 2.9) 0.3057 1.45 (0.68, 3.12) 0.3352
(70%) 1.44 (0.82, 2.51) 0.2048 1.67 (0.88, 3.17) 0.1199
(69%) . .
(65%) 0.84 (0.52, 1.33) 0.4525 0.73 (0.41, 1.3) 0.2788































Figure 1 Reasons for undergoing PSA test. % 1st ranked reason (blue). % 2nd ranked reason (red). % 3rd ranked reason (green).
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have been disclosed by GPs to more than 38% of respon-
dents. Disclosure of at least one risk was reported by
114 participants (61%). The number and proportion
advised of each potential risk are shown in Table 3.
Discussion
To our knowledge, this study is one of only a few which
have quantitatively examined men’s experiences of PSA
testing discussions and reasons for undergoing testing in
the Australian family practice setting. Sixty-seven per-
cent of participants reported having had a PSA test in
the past five years, and a further 14% discussed it with
their doctor. This rate is higher than that reported by
Slevin’s 1999 population-based survey in one Australian
state [21]. The latter study reported that 43% of men
aged 40 to 80 had undergone a PSA test, with most of
these (86%) having had their first test within the last
5 years. Gatellari’s study in Australian general practice
patients also identified lower rates of testing with only
23.6% of men aged 40–70 years indicating ever having a
PSA test and of those, 42% within the last year [25].
Baade’s study reported that 21% of men underwent PSA
testing in 2006 [2]; while Arnold-Reed’s study in five
family practices indicated that 59% of men aged 40–80
had undergone testing [19]. While this latter finding is
closer to the present findings, the results are not directly
comparable as no time-frame for testing was used.
Methodological differences between studies may accountTable 3 Number of respondents who report being advised ab
Received advice about potential risk (n = 188)
No clear evidence that PSA testing saves lives
PSA testing can lead to unnecessary treatments
Treatment for prostate cancer can lead to incontinence
Treatment for prostate cancer can lead to erectile dysfunction
Most prostate cancers will not affect a man’s health during his lifetimefor these discrepancies. Slevin’s data was based on a sur-
vey of randomly selected households, while our sample
consisted of men sampled from family practices. It is
possible that men recruited at a family practice are more
health conscious and thus more likely to undergo testing
than those in the general population. A second possibil-
ity is that rates of testing uptake have increased over
time, resulting in a higher reported rate of testing in the
present study compared to the Slevin, Gattelari and
Arnold-Reed studies [19,21,25]. Baade’s study was based
on health service use data over a 12 month period, and
so it is not possible to directly compare the current find-
ings with the 21% testing rate they reported [2].
Factors associated with screening participation
None of the socio-demographic characteristics examined
in the present study were found to be associated with
PSA testing. However, we found a trend that suggested
testing participation rates may be lower among men
aged 40–49 compared with older men. A previous Aus-
tralian study found that age was positively associated
with having had a PSA test [25]. However, as this associ-
ation was not explored within the last 5 years, results
are not directly comparable to the current study. A re-
cent Dutch study also found that men with chronic con-
ditions had higher rates of PSA testing [26], however we
found no association between chronic conditions and
PSA testing in the last 5 years. Differences in these find-
ings are likely explained by differences in the time pointsout possible risks of PSA testing
n (%) 95% CI for% Missing values
60 (35%) (27.5, 41.8) 15
28 (17%) (11.4, 23.2) 26
45 (29%) (22.0, 36.5) 34
53 (33%) (25.8, 40.5) 28
65 (38%) (30.5, 45.1) 16
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assessed. Previous research has also indicated that phys-
ician characteristics and attitude towards PSA testing
may also be associated with testing uptake [25,27]. It
was not possible to link patient responses to data on
physician characteristics in the current study, however,
this could be explored in future work.Reasons for participating in PSA testing
Of men who had undergone PSA testing, the most com-
mon top ranked reason was wanting to keep ‘up to date’
with health care testing (42%), followed by doctor rec-
ommendation to be tested based on symptoms (25%).
Previous Australian research found media publicity
(46%) and doctor recommendation (42%) were the two
main reasons for undertaking PSA testing [21]. There-
fore, the current findings may reflect increased aware-
ness of prostate cancer testing as a result of past media
campaigns. These results highlight the influence of GP
recommendation, patient perceptions of the need for
prostate testing, and the influence of the media, in de-
ciding to undertake testing. The fact that our findings
suggest that GPs initiate discussions for at least half of
PSA tests performed, but fail to adequately disclose the
risk of testing, supports the need for improvements in
physician’s communication with patients regarding the
appropriateness of PSA testing.How well are potential risks disclosed?
Our findings show most respondents indicated that dis-
cussion of PSA testing was initiated by their doctor
(54%) and that 61% of those who had either discussed or
undertaken a test in the past 5 years reported having
been advised about one or more risk relating to PSA
testing. Rates of discussion of specific risks varied from
17% to 38% with the risk of PSA testing leading to un-
necessary treatments having the lowest rate of disclos-
ure. Previous findings in this area are mixed. With
regards to patient-reported, doctor-initiated discussions
of PSA testing, studies in Australia have indicated the
occurrence of such discussions range from 25%- 41%
[28,29], yet studies in the US have suggested higher rates
(74%) [20]. Similarly, reported discussion of potential
risks are varied with a recent study showing as few as
11% of patients recalled being advised of potential risks
[28], while other studies are in accordance with our find-
ings [20,21]. A US study of 304 men attending general
internal medicine outpatient clinics found that men
knew about 50% of the prostate cancer facts assessed
[18]. Results are not, however, directly comparable due
to differences in the recruitment setting and differences
in the questions pertaining to knowledge of risks associ-
ated with testing.Practice implications
The present study indicates that a high proportion of
men in the Australian family practice setting undergo
PSA testing. While it was not possible to determine what
proportion of PSA testing would be considered clinically
appropriate in the current study, only 25% of men re-
ported the investigation of symptoms as one of the main
reasons for undergoing testing. However, based on our
data it is was not possible to draw conclusions about the
proportion of men who underwent testing who were
asymptomatic. Given potential difficulties in accuracy of
recall of symptoms over a 5 year period, it would be use-
ful for prospective research to examine the relationship
between symptom experience and the decision to un-
dertake a PSA test. It is important to identify rates of
inappropriate testing as this may have implications in
terms of over-diagnosis and treatment resulting in harms
to the patient [13], as well as inflation of health-care
costs.
Given high rates of testing uptake, it seems critical to
improve the rate at which key information about the
risks and benefits of PSA testing are discussed. Barriers
to such discussions may include patient or physician
attitudes or knowledge, and perceived lack of time for
discussions by doctors [30-32]. Further research is needed
to elucidate which factors may be most important to facili-
tating informed decision making for PSA testing, and test-
ing interventions targeted toward these.
Limitations
It is possible that the participating practices were not
representative of the broader family practice setting.
Comparison with data from practices participating in
the national Bettering the Evaluation and Care of Health
(BEACH) study, involving over 1000 GPs, however, re-
vealed that practices in the current study were similar to
those in BEACH in terms of the number of GPs
employed [33]. It is also possible that the men who par-
ticipated in the study were more health conscious or
health literate than those who did not consent. Given
the controversy over whether PSA testing is beneficial, it
is unclear if such differences would have led to under or
over-estimation of rates of PSA testing.
Verification of self-reported screening behavior with
medical records was beyond the scope of the present
study. A previous study has reported an accuracy rate of
74% for self-reported prostate screening among family
practice patients [34]; while a meta-analysis reported a
sensitivity of 71% and a specificity of 73% [35]. This sug-
gests that there is likely to be some degree of inaccuracy
in the self-report data obtained in the present study, our
data nevertheless provides a useful indication of the
men’s experiences of PSA testing and discussions within
the family practice setting.
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Despite debate over the benefits of routine PSA testing,
a high proportion of male family practice attendees re-
port participating in PSA testing. Men report that GP
recommendations for screening are influential in the de-
cision to be tested, however, overall risks associated with
testing appear to be poorly disclosed by GPs. These re-
sults suggest the need to improve the quality of informa-
tion provision about PSA testing in the family practice
setting.
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